Eli Lilly said Tuesday that it will limit the out-of-pocket cost of insulin to $35 per month. The move comes in response to offset the financial hardships due to the coronavirus pandemic.
The co-pay cap will cover the majority of the pharmaceutical company's insulin, including the humalog injection. The program is open to the uninsured as well as commercially insured people with type 1 diabetes, but the pharmaceutical company said it is not available to Medicaid, Medicare or Medicare Part D patients.
The savings can be obtained by calling the diabetes solution center toll-free line. Insulin prices spiked nearly 100% from 2012 to 2016.